The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.
F.D.A. Approves New Treatment for Early Alzheimer’s
The New York Times – Business:
This post first appeared in The New York Times – Business. Read the original article.
Written by
in